Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study.


BACKGROUND Safe/well-tolerated treatments for bipolar I depression remain limited. We assessed safety/tolerability of adjunctive open-label armodafinil, a wakefulness-promoting agent evaluated in 3 acute, controlled efficacy studies with variable efficacy results. METHODS Completers of three 8-week, double-blind, placebo-controlled adjunctive armodafinil… (More)
DOI: 10.1016/j.jad.2016.02.050


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics